<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460223</url>
  </required_header>
  <id_info>
    <org_study_id>NJLT006</org_study_id>
    <nct_id>NCT03460223</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis</brief_title>
  <official_title>Phase 1 Clinical Trial Using Mesenchymal Stem Cell as Individualized Medicine to Evaluate the Safety and Efficacy in Kidney Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney
      failure. The potential for stem cells to treat kidney failure was recently confirmed.
      Particularly, mesenchymal stem cell (MSC) has been demonstrated to protect kidney function
      and alleviating renal injury in these patients. Therefore, the investigators propose a
      hypothesis that MSCs (MSC) can also improve the disease conditions of kidney fibrosis
      patients, particularly reducing the decompensated conditions in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney fibrosis represents the common pathway to end-stage kidney failure.The potential for
      stem cells to treat kidney failure was recently confirmed. In particular, mesenchymal stem
      cell (MSC) transplantation has been applicated in the clinic for treat several human diseases
      such as GVHD, kidyney injury and displayed good tolerance and efficiency. The purpose of this
      study is to learn whether and how MSCs (MSC) can improve the disease conditions in patients
      with kidney fibrosis. This study will also look at safety in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BUN</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of BUN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cr</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of Cr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of eGFR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of Cystatin C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine protein</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of Urine protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hb</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of Hb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hct</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of Hct</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ca</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of Ca</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of P</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of PTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VitD</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of VitD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALB</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of ALB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TC</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of TC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>24 months</time_frame>
    <description>The evaluation of serum levels of TG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of renal fibrosis</measure>
    <time_frame>24 months</time_frame>
    <description>The pathology decrease in grade of renal fibrosis</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Conventional plus MSC treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC</intervention_name>
    <description>conventional plus MSC or placebo treatment</description>
    <arm_group_label>Conventional plus MSC treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent.

          2. Glomerular sclerosis ratio ≤ 50%.

          3. Renal tubulointerstitial fibrosis ratio ≤ 50%.

          4. Negative pregnancy test.

          5. Moderately active disease under standard treatment.

        Exclusion Criteria:

        1. Severe infection and cardiovascular disease, shock, secondary liver disease and
        malignant tumor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinhai Tang, M.D, PH.D</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Lu, M.D, PH.D</last_name>
    <phone>86-025-68136053</phone>
    <email>lvling@njmu.edu.cn</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Ling Lu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

